Gyre Therapeutics (GYRE) Misses Q2 EPS by 2c

Gyre Therapeutics (NASDAQ: GYRE) reported Q2 EPS of $0.00, $0.02 worse than the analyst estimate of $0.02. Revenue for the quarter came in at $26.8 million versus the consensus estimate of $28.7 million.

For earnings history and earnings-related data on Gyre Therapeutics (GYRE) click here.

You May Also Be Interested In

• BJ's Wholesale Club (BJ) Tops Q2 EPS by 19c, Beats on Revenue; Offers FY27 EPS Guidance
• LiveWire begins U.S. dealer deliveries of S4 Honcho Trail motorcycle
• Ross Stores (ROST) Tops Q2 EPS by 72c, Beats on Revenue